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Abstract 
Background Health technology assessment has been increasingly used in China, having been legally mandated in 
2019, to inform reimbursement decisions and price negotiations between the National Healthcare Security 
Administration and pharmaceutical companies around the price of new pharmaceuticals.  The criteria currently used 
to judge cost-effectiveness and inform pricing negotiations, 3x GDP per capita, is based on the rule of thumb 
previously recommended by the World Health Organization rather than an estimate based on an empirical 
assessment of health opportunity costs.   
Objective The objective of this study was to inform a cost-effectiveness threshold for health technology assessment 
in China that accounts for health opportunity cost.   
Methods The elasticity of health outcomes with respect to health expenditure was estimated using variations across 
30 provincial-level administrative divisions in 2017 controlling for a range of other factors and using an 
instrumental variable approach to account for endogeneity to assess robustness of results.  The estimated elasticity 
was then used to calculate the cost per DALY averted by variations in Chinese health expenditure at the margin.   
Results The range of estimates from this study, 27,923-52,247 (2017 RMB) (central estimate 37,446) per DALY 
averted or 47-88% of GDP per capita (central estimate 63%), shows that a cost per DALY averted cost-effectiveness 
threshold that reflects health opportunity costs is below 1x GDP per capita. 
Conclusion Our results suggest that the current cost-effectiveness threshold used in China is too high; continuing to 




Key points for decision makers 
• Health technology assessment has been increasingly used in China and the criteria currently used to judge cost-
effectiveness and inform pricing negotiations does not reflect an evidence-based assessment of health 
opportunity costs. 
• This article provides the first estimate of the marginal productivity of health expenditure in China which can be 
used to inform the health opportunity cost of funding a new technology.  
• Our central estimate 37,446 (2017 RMB) or 63% of GDP per capita shows that a cost per DALY averted cost-
effectiveness threshold that reflects health opportunity costs would be below 1x GDP per capita, suggesting that 
decisions made on the basis of the currently used 3x GDP per capita threshold risk resulting in net losses in 
overall population health.   
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Health technology assessment (HTA) has been increasingly used in China since its introduction in the 1990s.  With 
the support of key decision makers from the Chinese Ministry of Health, more than 15 academic institutions 
conducting HTA have been established across the country. The initial version of China Guidelines for 
Pharmacoeconomic Evaluations was published in 2011 to guide the HTA practice [1]. The HTA Research Network 
was established in 2016, led by National Health Commission (NHC)’s Health Development Research Centre, and has 
more than 300 members from universities, hospitals, and relevant associations as well as overseas experts.  In 2018, 
the National Centre for Evaluation of Medicines and Health Technologies was created by NHC, representing formal 
establishment of a national HTA agency [2–4].  
 
HTA has since been written into Government policy documents, including the Law of the People's Republic of China 
on the Promotion of Basic Medical and Health care, which was approved in December 2019 [5]. Following a 
successful pilot in 2017 to use HTA to inform the price negotiations for 44 medicines and medical devices that were 
considered innovative but expensive (and therefore not yet included in the National Formulary), HTA evaluation 
reports are now regularly requested by the National Healthcare Security Administration (NHSA) [6].  The NHSA has 
also established two assessment expert panels, one responsible for undertaking cost-effectiveness analysis and other 
for undertaking budget impact analysis.  
 
Whilst HTA is increasingly used in China to inform reimbursement decisions and price negotiations between the 
NHSA and pharmaceutical companies around the price of new pharmaceuticals, clearly defined and measurable 
criteria are still lacking.  One such example is the threshold used to judge cost-effectiveness, which is currently set at 
3x GDP per capita per disability-adjusted life year (DALY) averted [7].  This is based on historical World Health 
Organization (WHO) recommendations that a health technology costing less than 1x a country’s GDP per capita be 
considered highly cost-effective while a health technology costing less than 3x GDP per capita be considered cost-
effective.  The WHO has since recognised the shortcomings of using a GDP-based threshold, and consequently has 
stopped recommending their use as cost-effectiveness thresholds [8].   
 
It has, however, not followed this up with a recommendation of what should be used to inform cost-effectiveness 
thresholds in place of a GDP per capita based rule of thumb.  The Disease Control Priorities Network, which aims to 
set out priorities for disease control across the world, in its the most recent edition applies a threshold based upon 
health opportunity costs to judge cost-effectiveness [9].  Some countries also explicitly consider health opportunity 
costs.  The methods guidance for the UK’s national HTA agency, the National Institute for Health and Care Excellence 
(NICE), states that a technology can be considered cost effective if its health benefits are greater than the opportunity 
costs of technologies displaced to fund it [10].  In Canada, the cost-effectiveness threshold in the draft Patented 
Medicines Regulations (due to come into force in July 2020) set forth by the Patented Medicine Prices Review Board, 
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the Canadian body mandated to prevent pharmaceutical patentees from charging consumers excessive prices during 
the statutory monopoly period, is also based on estimates reflecting health opportunity costs [11].   
 
Assessing whether the expected health benefits of a new technology are greater than the opportunity costs of the other 
health technologies that could have been funded (whether these are currently funded health technologies that are 
displaced or other not currently funded health technologies that could be funded) requires an evidence-based 
assessment of the marginal productivity of health expenditure.  Research has been undertaken to estimate the marginal 
productivity of the healthcare system using within-country data for several countries, including the United Kingdom, 
Spain, Australia, the Netherlands, Sweden and South Africa [12–18].  However, such analyses are data and time 
intensive, and therefore not possible for all countries.  The Canadian estimate is instead based on work commissioned 
by the PMPRB to calculate the marginal cost of a QALY in the Canadian healthcare system using evidence from 
cross-country data as well as within-country estimates from the United Kingdom and evidence of historical trends in 
cost effectiveness assessments by Canadian HTA agencies, while commissioned within-country analysis is being 
undertaken [11]. 
 
To date, there are only two sources available for estimates that reflect the rate at which the Chinese healthcare system 
currently produces health.  Woods et al [19] expand upon previous work undertaken in the United Kingdom by 
applying data on the income elasticity of the value of health to extrapolate estimates for a wide range of countries 
including China. Ochalek et al [20] expand upon existing published estimates of the health effects of changes in 
expenditure from cross-country data to calculate a range of estimates for low- and middle-income countries (LMICs).  
Estimates based on within-country data are generally superior to those from cross-country data as cross-country 
analysis restricts the number of available variables owing to the need for international comparability. In addition, 
better identification strategies can typically be devised in the within-country context based on instrumental variable 
or natural experiment [21].   
 
This paper follows in the footsteps of previous research undertaken to estimate the marginal productivity of the 
healthcare system using within-country data for specific countries, and aims to provide an estimate of the cost per 
DALY averted for China that reflects health opportunity costs based on an evidence-based assessment of the marginal 
productivity of health expenditure in China.  Because an estimate of the marginal productivity of health expenditure 
reflects health opportunity costs, using it as a threshold to judge cost-effectiveness would ensure that decisions around 
whether or not to fund a health technology improve overall population health.  Such an estimate can also inform how 
much the healthcare system can afford to pay for a new technology for it to offer a net gain in health, which may be 





We begin by estimating the elasticity of health outcomes with respect to health expenditure per capita using 
variations across provincial-level administrative divisions, hereafter provinces, in mainland China in 20171 
controlling for a range of other factors.  We then conduct sensitivity analyses where we use an instrumental variable 
(IV) approach to account for potential endogeneity and increase the sample size by pooling data from 2011 to 2017.  
The data and methods used for the regression analyses are described in section 2.1.   
 
Calculating a cost per DALY averted estimate that reflects health opportunity costs requires two steps: first, 
estimating the elasticity of health outcomes with respect to health expenditure; and second, calculating cost per 
DALY averted from the estimated elasticity.  The data and methods used for this portion of the analysis are 
described in section 2.2. 
 
2.1 Estimating the effect of health expenditure on health outcomes 
2.1.1 Health outcomes 
Our paper considers three health outcomes: DALY rate (DALYs per 100,000 population), under-5 mortality (the 
cumulative probability of death by age 5 given being born) and adult mortality (the cumulative probability of death 
by age 60 given alive at age 15).  These variables reflect the kinds of health outcomes analysed in the wider 
literature examining their relationships with health expenditures [22].  Related studies generally tend to focus their 
analysis on mortality since this is widely recorded and is available for most countries.  In particular, under-5 
mortality is used because of international development goals that emphasise the importance of reducing avoidable 
mortality in this age group [23].  Some studies, however, have also considered adult working-age mortality since 
this is seen as an important step to achieving economic development [24].  Estimating the effect of healthcare on 
mortality, however, considers only part of the benefits of healthcare.  An analysis by disease-area found that over 
half of healthcare spending in the UK was spent on disease areas for which no mortality data was recorded [25].  It 
is likely that this kind of healthcare spending has effects on health not through mortality, but through improvements 
in health-related quality of life.  DALYs capture both the mortality and morbidity burden of disease that stands to be 
alleviated through health expenditure, and estimates of DALY burden are available for Chinese provinces from 
Zhou et al [26].  Analysing DALY health outcomes allows for the direct estimation of the effect of healthcare 
expenditure on a generic measure of health that incorporates both gains in survival and health-related quality of life. 
 
2.1.2 Health expenditure 
A key difference between this study and others is that we consider total health expenditure rather than government 
health expenditure only.  Over 95% of the Chinese population is covered by social health insurance, where the 
government pays a portion of the cost of care and patients pay the remainder through deductibles and copayments 
 
1 Most variables considered in the study are available only up to 2017. 
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[27,28].  For this reason, cost-effectiveness analysis takes a broader perspective with respect to costs compared to 
agencies such as the National Institute for Health and Care Excellent (NICE) in the UK.  For example, where a cost 
falls upon an individual (out of pocket) in China, this cost is included, whereas only costs falling on the National 
Health Service and Personal Social Services are typically included in the NICE reference case [7,10]. 
 
 
Studies estimating the marginal productivity of government health expenditure only are primarily useful for HTA 
bodies operating on behalf of primarily publicly financed health care systems and providing recommendations on 
the basis of improving health given a budget for health care that is exogenous to the decision.  In China health care 
is financed through a mix of sources and so HTA necessarily operates in a different decision context.  While ideally 
opportunity costs would be calculated separately for each component of expenditure, we combine them so that a 
single value for a cost-effectiveness threshold is estimated that is compatible with the approach to cost-effectiveness 
analysis typically undertaken in China for negotiating the price of pharmaceuticals. It could be that the health 
opportunity costs across different sources of financing are similar, if they are assumed to be equal then our results 
can be compared with estimates of marginal productivity of Chinese government health expenditure only.  
 
2.1.3. Control variables 
Our selection of control variables is informed by the literature review undertaken by Nakamura et al., (2016) [29] 
(See Appendix D of their review).  First, we obtained variables to control for the demographic profile of each 
province2: proportion of the population under age 14, proportion of population over age 65, and percentage of males 
in the population. 3   In addition, we obtained a number of variables that are potential determinants of the chosen 
health outcome variables: GDP per capita, percentage of population with at least a high school education, urbanicity 
rate, penetration rate of sanitary toilets, efficiency index of governance, and highway density.  They are all expected 
to have positive association with health – i.e. fewer DALYs and lower mortality.  These variables are all collected 
for the year 2017.  Additionally, we control for regional fixed effects by categorising provinces into East, Central 
and West regions.  Health is expected to be positively associated with the East region relative to the others [30].  To 
avoid issues of collinearity, variables that are too closely correlated with health expenditure per capita are excluded 
from the regression specification [29]4. All the variables used in the analysis are summarised in Table 1. 
[Insert Table 1 here] 
 
 
2 Our data exclude Tibet due to missing data.  This leaves us with a sample size of 30. 
3 The first two are only used when the health outcome is DALY rate since the other two are already age specific. 
4 We consider 0.7 as the threshold as too high correlation. 
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2.1.4 Regression analysis and endogeneity problems 
Analysis presented within the main paper considers the 2017 cross-section only. An additional panel analysis 
looking at 2011-2017 is conducted for the mortality outcomes (but not DALY, which is only available by province 
in 2017) and is presented in the Electronic Supplementary Material.5 
 
Our base case scenario is an ordinary least square (OLS) regression using the log transformed health outcomes as 
dependent variables and log transformed health expenditure per capita and control variables as predictors.  All the 
coefficient estimates can be interpreted as the elasticity of health outcomes with respect to a specific predictor.  The 
estimates are weighted using the population size of each province and robust standard errors are used.  The linear 
functional form assumption is tested for using ‘RESET’. 
 
There are two types of endogeneity problems that can arise when estimating the elasticity of health outcomes with 
respect to health expenditure.  The first is reverse causality, which is evident in many western healthcare systems 
where healthcare budget is determined using a formula based on previous years’ health outcomes [31].  By contrast, 
in China there is no such formula that is used to form the fiscal policy for healthcare, and reverse causality is 
therefore a lesser concern in our analysis [28].    Specifically, in China budget allocation is tied to capital investment 
and local fiscal capacity rather than the needs of facilities or the population [32].  Financial subsidies to public 
hospitals mainly fund capital construction and equipment acquisition, development of key disciplines, personnel 
training, retirees ‘expenses in line with state regulations and policy-related subsidies for losses [33].  When 
financing major public health service projects, local governments take the main responsibility for public health 
services and prevention of major communicable diseases within their jurisdictions, while central government 
provides subsidies for cross-regional projects.  Finally, different provider payment methods have been implemented 
whereby basic public health services are funded by financial provision per capita, while basic medical services are 
funded by basic medical insurance through mixed payment methods such as fee-for-service (the majority), case 
payment and global budget [28].   
 
The second type of endogeneity is related to the omitted variable bias which occurs when an unobserved confounder 
is associated with both the health outcome and health expenditure.  While controlling for a number of other 
determinants of health outcome reduces the likelihood of our estimates being contaminated by omitted variable bias, 
it may not be completely eliminated.  To formally test the exogeneity of health expenditure, we adopt an IV 
approach and consider two IVs: the average premium fees for Basic Medical Insurance among insured people and 
 
5 It would be ideal to control for provincial fixed effects. Unfortunately, there is insufficient within-province variation in the 
expenditure variable for this approach to be viable. We therefore chose to estimate pooled OLS , which is the same type of panel 
analysis that is undertaken in Siverskog and Henriksson (2019) [17]. 
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number of medical personnel per 10,000 people.  The rationale for the first and our primary IV (average premium 
fees for Basic Medical Insurance among insured people) is that, on average, the higher fees a person pays, the more 
health care services the person would consume.  Instrument exogeneity in this case relies upon the fee schedule by 
province not being related to health outcomes themselves or unobserved confounders between health expenditure 
and health outcomes, having controlled for a number of observable factors.  Note that these fees are compulsory for 
employed people in urban areas.  Moreover, out-of-pocket costs are typically induced for using these health care 
services (even if insured) which leads to higher expenditure.  The rationale for the second IV is that it represents the 
service capacity of the healthcare system.  China has a shortage of healthcare professionals [34], and so we expect 
that where more healthcare professionals are available to provide care, more healthcare is consumed and thus the 
higher health expenditure per capita is.  In this case instrument exogeneity relies on the distribution of shortages 
across provinces being unrelated to health outcomes or unobserved confounders between health outcomes and health 
expenditure. 
 
The IV regressions are implemented using the -ivreg2- Stata command.  The ‘gmm2s’ option is chosen for a two-
step feasible GMM estimation and the ‘small’ option for small-sample statistics.  The estimates are also weighted 
using the population size and robust standard errors are reported.  A number of tests are undertaken to check the 
validity of our IVs: underidentification test, weak identification test, overidentification test and endogeneity test.  
The linear functional form assumption is again tested for using ‘RESET’. 
 
One of the challenges of the IV approach is that one can never formally test the exclusive restriction, i.e., the IVs are 
not correlated with the error term in the original OLS regression, conditional on the other covariates.  Obviously, our 
IVs are correlated to economic and social development factors that would have direct impact on health outcomes.  
The question is therefore whether we have sufficiently controlled for these factors in the regression.  We will return 
to this in the discussion. 
2.3 Calculating cost per DALY averted from elasticities of the health effects of expenditure 
Informing an opportunity cost-based threshold requires calculating the DALYs averted from the estimated 
elasticities 𝜖 on DALYs or under-5 and adult mortality.  We apply the approach taken by Ochalek et al [20], which 
has also been used elsewhere [21,35].  The methods for moving from an estimate of the effect of expenditure on 
DALYs are explained in detail in Ochalek et al [20], and we summarise them here for calculating DALYs averted 
from an estimate of the effect of expenditure on mortality (DALY 1 in Ochalek et al, 2018) [20] and DALYs 




2.3.1 Using the estimated elasticity on mortality 
Calculating deaths averted 
Calculating cost per DALY averted from elasticities of the effect of expenditure on under-5 and adult mortality rates 
requires accounting for the age and gender structure of the population and applying a series of assumptions about 
survival and morbidity to obtain cost per DALY averted [20].  In our base case scenario, all data are taken from the 
Global Burden of Disease database for year 2017 [36].  We also present results using data on deaths and population 
by age and gender for 2017 based on Chinese census data [37].  Deaths by age and gender are calculated from 
mortality rates reported by age and gender from the 2010 China census (the most recent available) in combination 
with the population by age and gender from 2017 assuming that the death rate by age and gender has remained the 
same between 2010 and 2017.  DALYs are then calculated by combining data on deaths from the census with 
conditional life expectancy from GBD to calculate survival and using morbidity data from GBD. 
 
The first step is to calculate the deaths estimated to be averted from a change in expenditure.  Among children under 
5 this is calculated as: 𝑢𝑛𝑑𝑒𝑟 5 𝑑𝑒𝑎𝑡ℎ𝑠 𝑎𝑣𝑒𝑟𝑡𝑒𝑑 =  1% ∗ |𝜖𝑢𝑛𝑑𝑒𝑟 5 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦| ∗ 𝑢𝑛𝑑𝑒𝑟 5 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 
where under 5 mortality is the total number of deaths among children under 5 in 2017 in China. 
 
Among adults 15-60 this is calculated by applying the elasticity on adult mortality to deaths in each 5-year age 
category between ages 15 and 60 (i.e., 15-19, 20-24, 25-29, 30-34, 35-39, 40-44, 45-49, 50-54, 55-59): 
 𝑎𝑑𝑢𝑙𝑡 𝑑𝑒𝑎𝑡ℎ𝑠 𝑎𝑣𝑒𝑟𝑡𝑒𝑑 =  1% ∗ |𝜖𝑖𝑎𝑑𝑢𝑙𝑡 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦| ∗ 𝑑𝑒𝑎𝑡ℎ𝑠15−19 + ⋯ + 1% ∗ |𝜖𝑎𝑑𝑢𝑙𝑡 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦| ∗ 𝑑𝑒𝑎𝑡ℎ𝑠55− 59 
This assumes that the proportionate effect on adult mortality applies across age groups within the 15-60 age range. 
 
Calculating survival effects 
The survival effects of a change in expenditure are determined by applying conditional life expectancy at age of 
death (by 5-year age category) to the deaths averted (by 5-year age category).  This gives the years of life lost 
(YLLs) among children under 5 and adults 15-60.  While it may be the case that the same increase in healthcare 
expenditure would be expected to affect different age groups differently (and indeed, this is the rationale for 
estimating the effects on under-5s and adults separately), in the absence of good evidence to inform the extent to 
which the effects are likely to differ across age groups we assume that the same proportion of YLLs that are averted 
among these age groups are averted in the rest of the population.  In other words, if the calculated YLLs averted 
among children under 5 and adults 15-60 represent 40% of the YLLs in those combined age categories, then we 




Calculating morbidity effects 
Changes in expenditure are likely to affect morbidity in both directions: increases in burden of morbidity may results 
from increased survival, and decreases in morbidity may result from the direct effects of expenditure (e.g., on 
treating existing health conditions).  To account for the indirect effect, we apply the per capita YLD burden to the 
calculated survival effects (i.e., the YLL burden averted).  To account for the direct effect, we assume that the effect 
of changes in expenditure on morbidity is proportional to the effect on survival by applying the ratio of YLD to YLL 
to estimated survival effects [38].   
 
2.3.2 Using the estimated elasticity on DALYs 
Using the estimated elasticity of the effect of expenditure on DALYs is straightforward, and DALYs averted are 
simply calculated as: 𝐷𝐴𝐿𝑌𝑠 𝑎𝑣𝑒𝑟𝑡𝑒𝑑 =  1% ∗ |𝜖𝐷𝐴𝐿𝑌𝑠| ∗ 𝐷𝐴𝐿𝑌 𝑏𝑢𝑟𝑑𝑒𝑛 
 
Calculating DALYs averted 
The DALYs averted is the sum of the survival effects (i.e., YLLs averted) and the net morbidity effects (i.e., YLD 
averted: the direct effect minus the indirect effect).   
 
Calculating cost per DALY averted 
We are therefore able to calculate two estimates of cost per DALY averted.  The first is based upon the estimated 
DALYs averted calculated using the elasticity of the mortality effects of changes in expenditure.  The second is 
based upon the estimated DALYs averted calculated using the elasticity of the DALY effects of changes in 
expenditure.  Cost per DALY averted is calculated as: 
𝑐𝑜𝑠𝑡 𝑝𝑒𝑟 𝐷𝐴𝐿𝑌 𝑎𝑣𝑒𝑟𝑡𝑒𝑑 = 1% ∗ 𝑔𝑜𝑣𝑒𝑟𝑛𝑚𝑒𝑛𝑡 𝑒𝑥𝑝𝑒𝑛𝑑𝑖𝑡𝑢𝑟𝑒 𝑜𝑛 ℎ𝑒𝑎𝑙𝑡ℎ𝐷𝐴𝐿𝑌𝑠 𝑎𝑣𝑒𝑟𝑡𝑒𝑑  
3 Results 
3.1 Estimates of elasticity 
Correlation coefficient estimates among all candidate predictors are reported in Electronic Supplementary Material 
Table S1.  Health expenditure, education, urbanicity and GDP per capita are found to be highly correlated with each 
other, which suggests these four variables are likely to be determined by a common factor, such as the economic and 
social development level.  Given the high levels of correlation, the latter three are dropped from regression analyses.  
In addition to age and gender, the final model includes as controls three variables: government efficiency index, 
penetration rate of sanitary toilets and highway density. It is interesting that these three variables, in particular 
government efficiency index, are not strongly correlated with the aforementioned four variables. This may suggest 
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that they are capturing the residual impact of economic and social development level on health outcomes after 
including health expenditure as the main predictor. Finally, to control for other forms of heterogeneity, we include 
regional fixed effects. 
  
OLS estimates are presented in Table 2.6  The estimated elasticities are statistically significant at 5% significance 
level in all regressions.  Given a relatively small sample size, this suggests a very strong impact of health 
expenditure on health outcomes.  Based on these estimates, spending an additional 1% on healthcare would be 
expected to reduce the DALY rate by 0.271%, under-5 mortality rate by 0.448%, and adult mortality by 0.677% in 
2017 in China, controlling other factors.  
[Insert Table 2 here] 
 
Percentage of population under age 14 and percentage of population above age 65 both have positive impacts on 
DALY rate, and the latter is statistically significant.  Percentage of males in the population seems to have a negative 
effect on all three health outcome variables but the effect is not significant.  The government efficiency index has a 
negative and statistically significant effect on under-5 mortality, but its effect on DALYs and adult mortality is not 
statistically significant.  As expected, the penetration rate of sanitary toilets and highway density both have negative 
impacts on the outcomes.7 The regional effects included indicate a positive association with poor health, which is 
expected given that the reference region is East.  The ‘RESET’ test does not reject the linear functional form of 
covariate.  
 
While we are less concerned with the reverse causality, there is indeed a risk of omitted variable bias.  As discussed 
in the previous section, we adopt an IV approach to attempt tackle this potential problem.  The IV estimates are 
presented in Table 3 for the under-5 mortality rate outcome, Table 4 for the adult mortality rate outcome and Table 5 
for the DALY rate outcome.8  The IVs pass all three identification tests, i.e., there are no under, weak, and over 
identification problems.  Again, the ‘RESET’ test does not reject the linear functional form of covariate.  The 
endogeneity tests, however, suggest the exogeneity of health expenditure cannot be rejected based on the data.  This 
result is not surprising given the IV estimates of elasticity are very similar to their OLS counterparts.  Based on this, 
we use the OLS estimates to derive cost per DALY averted. 
 
6 Corresponding pooled OLS analysis looking at 2011-2017 for the mortality rate outcomes finds similar coefficient estimates. 
These results are presented in Table S2.  
7 The statistical insignificance may be caused by the relatively small sample size, e.g. large effect and large standard error at the 
same time.    
8 Corresponding pooled OLS IV estimates for the mortality rate outcome models are found in Tables S3 and S4, which provide 
very similar coefficient estimates. Again, in each case, the IVs pass all three identification tests. The endogeneity tests suggest 
the exogeneity of health expenditure cannot be rejected based on the data. 
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[Insert Tables 3, 4 and 5 here] 
 
3.2 Cost per DALY averted 
Table 6 presents the cost per DALY averted estimates calculated from the OLS model.  Applying the estimated 
elasticities from the OLS model on under-5 and adult mortality we find that it costs 27,923 (2017 RMB) to avert a 
DALY in China.  That is 47% of GDP per capita (4,131 2017 USD).  Applying the estimated elasticities from the 
OLS model on DALYs results in a higher estimate of 52,247 (2017 RMB) to avert a DALY in China (88% of GDP 
per capita, 7,730 2017 USD).  More DALYs are estimated to be averted when mortality elasticities are used than 
when an elasticity on DALYs is used.  Although a number of assumptions are required to get from the mortality 
effects of expenditure to cost per DALY averted, applying the estimated elasticity on DALYs to under-5 and adult 
mortality would result in a very similar estimate of DALYs averted.  This suggests that the assumptions employed 
are not unreasonable, and much of the difference in results between the two methods in our context is down to 
differences in the estimated elasticities.  
 [Insert Table 6 here] 
 
We also present results using data on deaths and population by age and gender for 2017 where survival effects are 
based on Chinese census data and morbidity effects are based on GBD data.  This results in higher estimates of cost 
per DALY averted because the census reports a lower mortality rate than GBD.  Applying the same elasticity to 
fewer deaths results in fewer deaths averted, lower survival effects and, because of the surrogacy assumption 
employed, a smaller effect on morbidity. 
 
The central estimate of cost per DALY averted is based on the average DALYs estimated to be averted using GBD 
data and census data based on the mortality effects of expenditure and the DALY effects of expenditure from the 
base case (OLS) analysis.  This is 1,404,658 DALYs averted for a 1% increase in health expenditure, suggesting 
China currently spends 37,4446 (2017 RMB) or 63% of GDP per capita (5,540 2017 USD) to avert one DALY.9 
  
4 Discussion  
This paper provides the first estimate of the marginal productivity of health expenditure in China based on Chinese 
province-level data, which can be used to inform the health opportunity cost of funding a new technology.  Our 
estimates are all below 1x GDP per capita, and therefore well below the 3x GDP per capita cost-effectiveness 
threshold widely used by scholars and policymakers in China.  China has not yet disclosed the ICER threshold for 
 
9 Calculating using an exchange rate of 0.148 for 2017 from the World Bank https://data.worldbank.org/indicator/PA.NUS.FCRF 
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drug price negotiation; it is clear that decisions made on the basis of the currently used 3x GDP per capita threshold 
risk resulting in net losses in overall population health 
 
The adoption of a cost-effectiveness threshold for decision-making in national medical insurance that is higher than 
an empirical estimate of the marginal productivity of healthcare expenditure may result in the introduction of drugs 
and technologies that generate less health than the health that would be generated by the same money required to 
fund them in the wider healthcare system, reducing total population health.  This is likely to lead to suboptimal 
resource allocation and thus a loss of social welfare.  Using a cost-effectiveness threshold that reflects the marginal 
productivity of the healthcare system also enables the inevitable trade-off in terms of population health forgone from 
approving a drug at a cost above the cost-effectiveness threshold to be made explicit, enabling greater transparency 
in decision-making.  Nonetheless, there may be challenges to implementing a cost-effectiveness threshold that is 
lower than what has been used previously and pharmaceutical companies may not necessarily adjust prices to reflect 
the prevailing cost-effectiveness threshold.  (See for example, the rejected recommendation to base the cost-
effectiveness threshold for the Joint Committee on Vaccination and Immunisation in the United Kingdom on 
available empirical evidence [39].)  Successful implementation requires strong political commitment, which China 
has in the Law of the People's Republic of China on the Promotion of Basic Medical and Health care [5].  It also 
requires institutional capacity, which exists in the National Centre for Evaluation of Medicines and Health 
Technologies and the wider HTA Research Network; standard methodological and process guidelines, i.e., the 
China Guidelines for Pharmacoeconomic Evaluations [1]; and strong enforcement [40]. 
 
HTA has become an important tool for national medical insurance coverage decisions.  Applying the China specific 
estimate of the marginal productivity of health expenditure produced in this study as a cost-effectiveness threshold 
for China would have wide-ranging implications and applications.  For example, the threshold may be applied to 
drug negotiation and pricing decisions by the NHSA.  The NHSA economic evaluation team participated in the 
national drug negotiations of 2017 where cost effectiveness results were an important basis for the negotiations.  
This study provides an evidence-based estimate of cost per DALY averted that may be used as a cost-effectiveness 
threshold by the evaluation team, and which would ensure negotiations could be informed by estimates of the health 
opportunity cost of approving a drug at a given price and the expected net benefits of different potential prices.  
 
The threshold may also benefit health resource allocation decisions at local levels.  The governments of many cities 
in China, such as Shanghai, Beijing and Guangzhou now require HTA evidence when setting the price for new 
medical services.  Whilst not compulsory, HTA is also increasingly used by local governments to assist their 
evaluation of public health interventions and medical technology disinvestments.  For example, economic evaluation 
of colorectal cancer screening and pneumonia vaccine projects have been undertaken in many cities as an important 




The threshold may well have impact on hospitals’ procurement decisions of medical devices as well.  Since 2016, 
the NHC has been promoting the use of HTA in hospitals’ purchase decisions.  This campaign has been very 
successful and many hospitals across China have now included HTA evidence in their procurement of medical 
devices on a regular basis [41].  
 
The range of estimates from this paper, 27,923-52,247 (2017 RMB) (central estimate 37,466) per DALY averted or 
47-88% of GDP per capita (central estimate 63%), is consistent with, albeit slightly higher than, previous estimates 
from cross-country analyses.  Woods et al [19] report a range of 1,151-4,550 (2013 USD) or 17-67% of GDP per 
capita per QALY gained for China based on extrapolating the UK estimate of the health effects of a change in 
expenditure on health outcomes using the income elasticity of the value of health to estimate ranges of cost per 
QALY estimates across countries.  Ochalek et al [20] report a range of 3,650-5,076 (2015 USD) or 45-63% of GDP 
per capita per DALY averted based on expanding existing published estimates of the health effects of changes in 
expenditure on health outcomes and applying these to country-specific data on health expenditure, epidemiology and 
demography to calculate a range of cost per DALY averted estimates for low and middle-income countries.   
 
Cost per DALY averted or QALY gained thresholds can both be used to judge estimates of cost-effectiveness where 
benefits are reported in QALYs or DALYs [42].  QALYs and DALYs are the two most commonly used measures of 
health that account for both length and quality of life.  While there are methodological differences between the two, 
given the absence of an accepted method for translating between the two they can be used interchangeably (e.g., as 
in the United States [43] [44]).  Published cost-effectiveness analyses in China may use either [45], but recent 
research has shown that differences in cost per QALY or DALY ratios for the same intervention do not materially 
affect comparisons of these ratios to thresholds [42]. 
 
Estimating the health opportunity costs of committing expenditure to a particular investment hinges on an empirical 
question linking expenditures to their estimated effects on health outcomes.  While this study considers a specific 
approach to answering this question, there may be alternative strategies worthy of consideration for future work.  
The approach taken in this paper is to derive an estimate based on an elasticity estimated using a cross-sectional 
analysis of Chinese province-level data, which constrained our analysis to including only a small number of control 
variables that can measure economic and social development levels that might confound the relationship between 
expenditure and health.  This may affect the accuracy of our elasticity estimates, but such concerns can be alleviated 
by our careful selection of socioeconomic control variables and the sensitivity analyses undertaken. Nevertheless, 
future work may consider alternative approaches to allowing for unobserved confounders such as using different 
instrumental variables or identifying natural experiments that lead to exogenous variations in health expenditure.  It 
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could also investigate this relationship using a more granular geographical unit of analysis so that more observations 
are available and there is greater ability to control for observable confounders.  In addition, efforts to collect more 
data by province could assist estimation of elasticities of effect and their translation into a cost per DALY averted. 
 
Once framed as an empirical question, a number of related research questions bear further consideration.  Due to the 
vast heterogeneity among provinces in China, the effects of total health expenditure on health outcomes would be 
expected to vary across these if health care resources were not allocated across provinces to maximise total 
population health (in such a case marginal productivities should be equal).  This coupled with the considerable 
autonomy that provinces have over decision-making in health means that establishing region-specific marginal 
productivity of expenditure is a research priority.  Another important question concerns the appropriate mix of 
health care financing.  If we could analyse the distribution of health opportunity costs of different types of health 
expenditure separately then decisions around levels of copayments to be levied could be informed.  
 
5 Conclusion 
This paper provides an estimate of cost per DALY averted that reflects health opportunity costs in the Chinese 
healthcare system by considering the elasticity of health outcomes with respect to health expenditure, estimated using 
variations between provinces in 2017 controlling for a range of other factors and using an instrumental variable 
approach to account for endogeneity. The estimated elasticity is used to calculate the cost per DALY of variations in 
Chinese health expenditure at the margin.  Our estimate 37,466 (2017 RMB) or 63% of GDP per capita (5,540 2017 
USD) shows that a cost per DALY averted cost-effectiveness threshold that reflects health opportunity costs would 
be below 1x GDP per capita, suggesting that decisions made on the basis of the currently used 3x GDP per capita 





[1] Liu G, Hu S, Wu J. China Guidelines for Pharmacoeconomic Evaluations. China J Pharm Econ (in 
Chinese). 2011;(3):6–48.  
[2] Wang H, Jin C, Bai F, Lin X, Fang L, Sun H, et al. Driving factors and mode transformation regarding 
health technology assessment (HTA) in China: Problems and recommendations. Biosci Trends. 2019 May 
12;13(2):110–6.  
[3] Chen Y, Chi X, He Y, Wei Y, Oortwijn W, Shi L. Mapping of Health Technology Assessment in China: 
Situation Analysis and International Comparison. Int J Technol Assess Health Care. 2019;35(5):401–7.  
[4] Chen Y, He Y, Chi X, Wei Y, Shi L. Development of health technology assessment in China: New 
challenges. Biosci Trends. 2018;12(2):102–8.  
[5] China CPGO. Basic Healthcare and Health Promotion Law [Internet]. 2019. Available from: 
https://npcobserver.com/lawlist/basic-healthcare-and-health-promotion-law/ 
[6] Li H, Liu GG, Wu J, Wu JH, Dong CH, Hu SL. Recent Pricing Negotiations on Innovative Medicines Pilot 
in China: Experiences, Implications, and Suggestions. Value Heal Reg Issues. 2018 May 1;15:133–7.  
[7] Liu GG, editor. China guidelines for pharmacoeconomic evaluations (Chinese-English version). Beijing: 
China Market Press; 2020.  
[8] Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny M-P, et al. Policy &amp; practice 
Cost–effectiveness thresholds: pros and cons Thresholds based on gross domestic product. Bull World Heal 
Organ. 2016;94:925–30.  
[9] Horton S. Cost-Effectiveness Analysis in Disease Control Priorities, Third Edition. In: Jamison DT, Gelband 
H, Horton S, Jha P, Laxminarayan R, Mock CN, et al., editors. Disease Control Priorities in Developing 
Countries. 3rd Editio. The World Bank; 2017.  
[10] National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 
2013 [Internet]. London; 2013. Available from: http://www.nice.org.uk/article/pmg9/resources/non-
guidance-guide-to-the-methods-of-technology-appraisal-2013-pdf 
[11] The Patented Medicine Prices Review Board. PMPRB Guidelines 2019 [Internet]. Ottawa; 2019. Available 
from: www.pmprb-cepmb.gc.ca 
[12] Edney LC, Haji Ali Afzali H, Cheng TC, Karnon J. Estimating the Reference Incremental Cost-
Effectiveness Ratio for the Australian Health System. Pharmacoeconomics. 2018 Dec 22;36:239–52. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/29273843 
[13] Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the 
Spanish NHS. Heal Econ (United Kingdom). 2018 Apr 1;27(4):746–61.  
[14] Stadhouders N, Koolman X, Dijk C, Jeurissen P, Adang E. The marginal benefits of healthcare spending in 
the Netherlands: Estimating cost‐effectiveness thresholds using a translog production function. Health Econ. 
2019 Nov 30;28(11):1331–44.  
[15] van Baal P, Perry-Duxbury M, Bakx P, Versteegh M, van Doorslaer E, Brouwer W. A cost-effectiveness 
threshold based on the marginal returns of cardiovascular hospital spending. Health Econ. 2019 
Jan;28(1):87–100.  
[16] Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the Estimation of the 




[17] Siverskog J, Henriksson M. Estimating the marginal cost of a life year in Sweden’s public healthcare sector. 
Eur J Heal Econ. 2019 Jul 1;20(5):751–62.  
17 
 
[18] Edoka IP, Stacey NK. Estimating a cost-effectiveness threshold for health care decision-making in South 
Africa. Health Policy Plan. 2020 Jun 1;35(5):546–55.  
[19] Woods B, Revill P, Sculpher M, Claxton K. Country-Level Cost-Effectiveness Thresholds: Initial Estimates 
and the Need for Further Research. Value Heal. 2016 Dec;19(8):929–35.  
[20] Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and middle-income 
countries: a novel approach and evidence from cross-country data. BMJ Glob Heal. 2018 Nov 
5;3(6):e000964.  
[21] Ochalek J, Lomas J. Reflecting the health opportunity costs of funding decisions within value frameworks: 
Initial estimates and the need for further research. Clin Ther. 2020 Jan 1;42(1):44-59.e2.  
[22] Gallet CA, Doucouliagos H. The impact of healthcare spending on health outcomes: A meta-regression 
analysis. Soc Sci Med. 2017 Apr;179:9–17.  
[23] Filmer D, Pritchett L. The impact of public spending on health: does money matter? Soc Sci Med. 1999 
Nov;49(10):1309–23.  
[24] Moreno-Serra R, Smith PC. Broader health coverage is good for the nation’s health: evidence from country 
level panel data. J R Stat Soc Ser A Stat Soc. 2015 Jan;178(1):101–24. 
[25] Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the 
National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015 
Feb;19(14):1–503, v–vi.  
[26] Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, et al. Mortality, morbidity, and risk factors in China and 
its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019 
Sep 28;394(10204):1145–58.  
[27] Yip W, Fu H, Chen AT, Zhai T, Jian W, Xu R, et al. 10 years of health-care reform in China: progress and 
gaps in Universal Health Coverage. Vol. 394, The Lancet. Lancet Publishing Group; 2019. p. 1192–204.  
[28] World Health Organization. Regional Office for the Western Pacific. People’s Republic of China health 
system review [Internet]. Manila; 2015. Available from: https://iris.wpro.who.int/handle/10665.1/11408 
[29] Nakamura R, Lomas J, Claxton K, Bokhari F, Serra RM, Suhrcke M. CHE Research Paper 128 Assessing 




[30] Yuan P, Chen T, Lin X. Analysis of differences in life expectancy across the east, central and west regions 
of China. Chinese J Prev Med. 2014;48(8):739–40.  
[31] Andrews M, Elamin O, Hall AR, Kyriakoulis K, Sutton M. Inference in the presence of redundant moment 
conditions and the impact of government health expenditure on health outcomes in England. Econom Rev. 
2017 Mar 16;36(1–3):23–41.  
[32] Xu J, Jian W, Zhu K, Kwon S, Fang H. Reforming public hospital financing in China: Progress and 
challenges. BMJ. 2019 Jun 21;365:20–4.  
[33] National Health Commission of the PRC. Guiding Opinions of the General Office of the State Council on 
urban public hospital comprehensive reform pilot [Internet]. Beijing; 2015. (国办发). Report No.: 38. 
Available from: http://www.nhc.gov.cn/tigs/s3581/201505/6c4713d7d40e4b6cb3f1db173143c296.shtml 
[34] Wu Q, Zhao L, Ye X-C. Shortage of healthcare professionals in China. BMJ. 2016 Sep 22;354:i4860.  
[35] Ochalek J, Lomas J, Claxton K. Assessing health opportunity costs for the Canadian health care systems. 




[36] Global Burden of Disease Study 2017 (GBD 2017) Data Resources | GHDx [Internet]. Available from: 
http://ghdx.healthdata.org/gbd-2017 
[37] China Statistical Yearbook 2018 [Internet]. Beijing; 2018. Available from: 
http://www.stats.gov.cn/tjsj/ndsj/2018/indexeh.htm 
[38] Soares MO, Sculpher MJ, Claxton K. Health Opportunity Costs: Assessing the Implications of Uncertainty 
Using Elicitation Methods with Experts. Med Decis Mak. 2020 May 22;0272989X2091645.  
[39] UK Department of Health and Social Care. Cost-effectiveness methodology for Immunisation Programmes 
and Procurements (CEMIPP) The government’s decision and summary of consultation responses [Internet]. 
London; 2019. Available from: 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/707847/c 
[40] Teerawattananon Y, Tritasavit N, Suchonwanich N, Kingkaew P. The use of economic evaluation for 
guiding the pharmaceutical reimbursement list in Thailand. Z Evid Fortbild Qual Gesundhwes. 
2014;108(7):397–404.  
[41] Lin X, Bai F, Lv L, Wang H, He J, Jin C. Exploration and research on hospital-based technology assessment 
in China. Chinese J Evidence-based Med (in Chinese). 2020;20(1):95–7.  
[42] Feng X, Kim DD, Cohen JT, Neumann PJ, Ollendorf DA. Using QALYs versus DALYs to measure cost-
effectiveness: How much does it matter? Int J Technol Assess Health Care. 2020;1–8.  
[43] Cameron D, Ubels J, Norström F. On what basis are medical cost-effectiveness thresholds set? Clashing 
opinions and an absence of data: a systematic review. Vol. 11, Global Health Action. Taylor and Francis 
Ltd.; 2018.  
[44] Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan. 2006 Jul 
28;21(5):402–8.  
[45] Butt T, Liu GG, Kim DD, Neumann PJ. Taking stock of cost-effectiveness analysis of healthcare in China. 
BMJ Glob Heal. 2019 May 1;4(3).  
[46] China Health Statistical Yearbook 2018. Beijing: Peking Union Medical College Publishing House; 2018.  
[47] Educational Statistics Yearbook of China [Internet]. Beijing: China Statistics Press; 2017. Available from: 
http://cdi.cnki.net/Titles/SingleNJ?NJCode=N2019030252 
[48] Zhang Z. Development prospect appraisal report for Chinese provinces and cities 1990-2018. In: Nan Y, 
editor. Annual report on China’s economic growth 2017-2018. Beijing: Social Sciences Academic Press; 
2018. p. 50–284.  
[49] China TND and RC of the PR of. China Transportation and Communications Yearbook 2018. Beijing: 








Table 1. Variables and their definition and source 
Variable name Definition Source 
DALY DALYS per 100,000 people Zhou et al (2019) [26] 
U5 mortality Under age 5 mortality, i.e., the number of deaths by age 5 given being born per 1,000 people Zhou et al (2019) [26] 
Adult mortality The number of deaths by age 60 given alive at age 15 per 1,000 people Zhou et al (2019) [26] 
hcepc Health expenditure per capita (RMB) 
China Health Statistical Yearbook 2018 
[46] 
population Size of population (in 10,000) China Statistical Yearbook 2018 [37] 
u14 The number of people under age 14 per 100 people 
China Health Statistical Yearbook 2018 
[46] 
a65 The number of people over age 65 per 100 people 
China Health Statistical Yearbook 2018 
[46] 
male The number of males in the population per 100 people China Statistical Yearbook 2018 [37] 
urban The number of people living in urban areas per 100 people China Statistical Yearbook 2018 [37] 
edu The number of people with at least high school education level per 100 people 
Education Statistics Yearbook of China 
2017 [47] 
gdppc GDP per capita (RMB) China Statistical Yearbook 2018 [37] 
toilets 
Penetration rate of sanitary toilets, i.e., the accumulated number of sanitary toilets divided by 
the total number of households in rural area (X100) 
China Health Statistical Yearbook 2018 
[46] 
gov 
Government efficiency index, measuring efficiency of public service and social security. The 
former includes the degree of marketisation, the number of service facilities in urban 
communities, traffic accidents, fire accidents, infrastructure. The latter includes the coverage of 
pension for urban workers, the coverage of basic medical insurance in urban areas, and the 
coverage of unemployment insurance in urban areas   
Zhang (2018) [48] 
highway Highway density in terms of land area (km/100 km^2) 
China Transportation and 
Communications Yearbook 2018 [49] 
medper The number of medical personnel per 10,000 people 
China Health Statistical Yearbook 2018 
[46] and & China Statistical Yearbook 
2018 [37] 
insurfee Average premier fees for Basic Medical Insurance (for all insured people) China Statistical Yearbook 2018 [37] 
east 
East region: Beijing, Tianjin, Hebei, Liaoning, Shanghai, Jiangsu, Zhejiang, Fujian, Shandong, 
Guangdong, Hainan  
 
central Central region: Heilongjiang, Jilin, Shanxi, Anhui, Jiangxi, Henan, Hubei, Hunan  
west 
West region: Neimenggu, Guangxi, Chongqing, Sichuan, Guizhou, Yunnan, Tibet, Shaanxi, 
Gansu, Qinghai, Ningxia, Xinjiang 
 
Note: All the variables are for the provincial-level administrative divisions in mainland China except Tibet (so the sample size is 30). 
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Table 2. OLS estimates: elasticity of health outcomes with respect to health expenditure 
 (1) (2) (3) 
 U5 mortality Adult mortality DALY 
VARIABLES OLS OLS OLS 
    
hcepc -0.448*** -0.677*** -0.271** 
 [0.142] [0.097] [0.097] 
u14   0.039 
   [0.134] 
a65   0.369** 
   [0.162] 
male -0.602 -1.328 -0.767 
 [1.992] [1.208] [1.415] 
gov -0.512*** 0.001 -0.052 
 [0.115] [0.141] [0.073] 
toilets -0.129 -0.052 -0.031 
 [0.280] [0.204] [0.161] 
highway 0.002 -0.112** -0.077 
 [0.079] [0.051] [0.047] 
central 0.113 0.019 0.009 
 [0.101] [0.077] [0.044] 
west 0.468*** 0.148* 0.038 
 [0.139] [0.076] [0.059] 
Constant 11.658 15.895*** 15.185** 
 [8.381] [4.694] [6.041] 
    
Observations 30 30 30 
R-squared 0.823 0.809 0.782 
RESET p-value 0.947 0.602 0.392 
Note:  
1. All the variables are log transformed.  
2. Robust standard errors are in the bracket.  




Table 3. IV OLS estimates: elasticity of under-5 mortality with respect to health expenditure 
 (1) (2) (3) 
 U5 mortality U5 mortality U5 mortality 
 IV IV IV 
VARIABLES fund income health professionals fund income and health professionals 
    
hcepc -0.399** -0.432*** -0.428*** 
 [0.172] [0.113] [0.115] 
male -0.513 -0.572 -0.527 
 [1.961] [1.958] [1.953] 
toilets -0.147 -0.135 -0.115 
 [0.290] [0.265] [0.252] 
gov -0.512*** -0.512*** -0.510*** 
 [0.117] [0.116] [0.116] 
highway 0.003 0.002 0.008 
 [0.078] [0.079] [0.073] 
central 0.125 0.117 0.119 
 [0.098] [0.093] [0.094] 
west 0.475*** 0.471*** 0.481*** 
 [0.134] [0.140] [0.131] 
Constant 10.981 11.430 11.091 
 [8.031] [8.117] [7.982] 
    
Observations 30 30 30 
K-P F statistic 75.38 37.87 136.7 
Endog test p-value 0.522 0.861 0.536 
IVRESET test p-value 0.333 0.738 0.433 
Under id test p-value 0.0117 0.0176 0.0380 
Over id test p-value   0.794 
Note: 1. All the variables are log transformed. 2. Robust standard errors are in the bracket. 3. Statistical significance: *=10%,**=5%,***=1%. 
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Table 4. IV OLS estimates: elasticity of adult mortality with respect to health expenditure 
 (1) (2) (3) 
 Adult mortality Adult mortality Adult mortality 
 IV IV IV 
VARIABLES fund income health professionals fund income and health professionals 
    
hcepc -0.697*** -0.618*** -0.685*** 
 [0.112] [0.152] [0.112] 
male -1.364 -1.221 -1.387 
 [1.224] [1.316] [1.245] 
toilets -0.045 -0.074 -0.042 
 [0.204] [0.220] [0.207] 
gov 0.001 0.001 -0.002 
 [0.141] [0.141] [0.141] 
highway -0.112** -0.111** -0.105** 
 [0.052] [0.051] [0.050] 
central 0.014 0.033 0.023 
 [0.079] [0.085] [0.080] 
west 0.145* 0.156* 0.153* 
 [0.076] [0.081] [0.077] 
Constant 16.171*** 15.077** 16.130*** 
 [4.889] [5.498] [5.008] 
    
Observations 30 30 30 
K-P F statistic 75.38 37.87 136.7 
Endog test p-value 0.704 0.424 0.766 
IVRESET test p-value 0.629 0.253 0.546 
Under id test p-value 0.0117 0.0176 0.0380 
Over id test p-value   0.455 




Table 5. IV OLS estimates: elasticity of DALY with respect to health expenditure 
 (1) (2) (3) 
 DALY DALY DALY 
 IV IV IV 
VARIABLES fund income health professionals fund income and health professionals 
    
hcepc -0.280** -0.228 -0.260** 
 [0.130] [0.152] [0.108] 
u14 0.030 0.080 0.061 
 [0.172] [0.152] [0.137] 
a65 0.363* 0.402** 0.380** 
 [0.176] [0.192] [0.171] 
male -0.811 -0.553 -0.759 
 [1.454] [1.682] [1.478] 
toilets -0.025 -0.061 -0.043 
 [0.176] [0.180] [0.167] 
gov -0.053 -0.050 -0.049 
 [0.074] [0.074] [0.073] 
highway -0.076 -0.085* -0.082* 
 [0.053] [0.048] [0.047] 
central 0.008 0.011 0.005 
 [0.043] [0.046] [0.042] 
west 0.040 0.030 0.031 
 [0.064] [0.058] [0.057] 
Constant 15.440** 13.944* 15.030** 
 [6.416] [7.580] [6.415] 
    
Observations 30 30 30 
K-P F statistic 30.29 13.59 43.18 
Endog test p-value 0.883 0.622 0.691 
IVRESET test p-value 0.474 0.549 0.431 
Under id test p-value 0.0121 0.0206 0.0373 
Over id test p-value   0.703 




Table 6. Cost per DALY averted 
 
Data source Global Burden of Disease China Census 
Central estimate 
Elasticity 
U5 and adult 
mortality 
DALY 
U5 and adult 
mortality 
DALYs averted 1,883,715 1,006,725 1,323,534 1,404,658 
Cost per DALY averted (2017 RMB) 27,923 52,247 39,741 37,446  
Cost per DALY averted (2017 USD) 4,131 7,730 5,880 5,540  
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Table S1. Correlations across candidate regressors 
  hcepc u14 a65 male edu urban gdp gov toilets highway 
hcepc 1.000                   
u14 -0.603*** 1.000                 
a65 0.196 -0.599*** 1.000               
male -0.081 0.128 -0.356* 1.000             
edu 0.802*** -0.702*** 0.292 -0.100 1.000           
urban 0.800*** -0.744*** 0.394** 0.047 0.863*** 1.000         
gdp 0.794*** -0.595*** 0.381** 0.046 0.777*** 0.928*** 1.000       
gov 0.065 -0.072 0.313* -0.079 0.026 0.211 0.387** 1.000     
toilets 0.363** -0.261 0.222 0.401* 0.349* 0.513** 0.553** 0.294 1.000   
highway 0.101 -0.203 0.539*** 0.154 0.273 0.432** 0.463** 0.437** 0.332* 1.000 
 
Note: 
1. All the variables are log transformed 
2. Statistical significance: *=10%,**=5%,***=1% 
 
 
Table S2. Pooled OLS estimates: elasticity of health outcomes (two mortality rates) with respect to health 
expenditure 
 (1) (2) 
 U5 mortality Adult mortality 
VARIABLES Pooled OLS Pooled OLS 
   
hcepc -0.460*** -0.637*** 
 [0.115] [0.078] 
male -0.298 -1.411*** 
 [1.255] [0.438] 
toilets 0.010 -0.170 
 [0.226] [0.132] 
gov -0.507*** 0.002 
 [0.105] [0.122] 
Highway -0.029 -0.137*** 
 [0.075] [0.042] 
Central 0.136 -0.003 
 [0.090] [0.055] 
West 0.475*** 0.068 
 [0.124] [0.057] 
year2012 0.051** 0.095*** 
 [0.020] [0.014] 
year2013 0.106*** 0.171*** 
 [0.037] [0.028] 
year2014 0.155*** 0.234*** 
 [0.051] [0.038] 
year2015 0.217*** 0.315*** 
 [0.066] [0.049] 
year2016 0.255*** 0.393*** 
 [0.086] [0.060] 
year2017 0.259** 0.445*** 
 [0.100] [0.069] 
Constant 9.801* 16.102*** 
 [5.387] [1.980] 
   
Observations 210 210 
R-squared 0.827 0.837 
RESET p-value 0.117 0.189 
 
Note: 
1. All the variables are log transformed. 
2. Robust standard errors are in the bracket. 




Table S3. IV pooled OLS estimates: elasticity of under age 5 mortality with respect to health expenditure 
 (1) (2) (3) 
 U5 mortality U5 mortality U5 mortality 
 IV IV IV 
VARIABLES fund income health professionals fund income and health professionals 
    
hcepc -0.399** -0.450*** -0.440*** 
 [0.149] [0.113] [0.111] 
male -0.206 -0.282 -0.402 
 [1.313] [1.261] [1.231] 
toilets -0.014 0.006 0.001 
 [0.229] [0.223] [0.224] 
gov -0.506*** -0.507*** -0.515*** 
 [0.109] [0.105] [0.105] 
highway -0.026 -0.029 -0.031 
 [0.075] [0.074] [0.074] 
central 0.151 0.139 0.130 
 [0.102] [0.088] [0.087] 
west 0.485*** 0.477*** 0.459*** 
 [0.134] [0.125] [0.119] 
year2012 0.043 0.050** 0.049** 
 [0.025] [0.020] [0.021] 
year2013 0.090* 0.103*** 0.102*** 
 [0.048] [0.036] [0.036] 
year2014 0.132** 0.151*** 0.149*** 
 [0.064] [0.049] [0.050] 
year2015 0.188** 0.212*** 0.210*** 
 [0.085] [0.063] [0.064] 
year2016 0.218* 0.249*** 0.245*** 
 [0.108] [0.085] [0.086] 
year2017 0.216* 0.252** 0.250** 
 [0.127] [0.096] [0.097] 
Constant 9.051 9.673* 10.158* 
 [5.913] [5.434] [5.319] 
    
Observations 210 210 210 
K-P F statistic 16.39 63.81 67.28 
Endog test p-value 0.490 0.876 0.610 
IVRESET test p-value 0.853 0.672 0.905 
Under id test p-value 0.0425 0.0139 0.0428 
Over id test p-value   0.640 
 
Note: 
1. All the variables are log transformed. 
2. Robust standard errors are in the bracket. 
3. Statistical significance: *=10%,**=5%,***=1% 
 
Table S4. IV pooled OLS estimates: elasticity of adult mortality with respect to health expenditure 
 (1) (2) (3) 
 Adult mortality Adult mortality Adult mortality 
 IV IV IV 
VARIABLES fund income health professionals fund income and health 
professionals 
    
hcepc -0.654*** -0.594*** -0.629*** 
 [0.103] [0.106] [0.096] 
male -1.437*** -1.347*** -1.425*** 
 [0.455] [0.483] [0.468] 
toilets -0.163 -0.186 -0.171 
 [0.139] [0.144] [0.140] 
gov 0.001 0.003 0.006 
 [0.122] [0.122] [0.122] 
highway -0.138*** -0.134*** -0.134*** 
 [0.041] [0.042] [0.042] 
central -0.007 0.008 0.000 
 [0.057] [0.060] [0.058] 
west 0.065 0.075 0.064 
 [0.053] [0.060] [0.057] 
year2012 0.097*** 0.088*** 0.092*** 
 [0.018] [0.017] [0.016] 
year2013 0.176*** 0.159*** 0.167*** 
 [0.034] [0.033] [0.032] 
year2014 0.240*** 0.218*** 0.230*** 
 [0.045] [0.045] [0.043] 
year2015 0.324*** 0.295*** 0.310*** 
 [0.059] [0.059] [0.055] 
year2016 0.403*** 0.367*** 0.386*** 
 [0.073] [0.073] [0.069] 
year2017 0.458*** 0.415*** 0.438*** 
 [0.084] [0.084] [0.079] 
Constant 16.313*** 15.578*** 16.066*** 
 [2.163] [2.347] [2.230] 
    
Observations 210 210 210 
K-P F statistic 16.39 63.81 67.28 
Endog test p-value 0.769 0.454 0.755 
IVRESET test p-value 0.270 0.736 0.664 
Under id test p-value 0.0425 0.0139 0.0428 
Over id test p-value   0.438 
 
Note: 
1. All the variables are log transformed. 
2. Robust standard errors are in the bracket. 
3. Statistical significance: *=10%,**=5%,***=1% 
